Haemodynamic observations with KO. 1366 (bunitrolol), a new beta-adrenergic blocking agent

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chest pain necessitates investigation into new therapeutic agents.
• Beta-adrenergic blocking agents are crucial in managing cardiovascular conditions.

Purpose of the Study:

• To evaluate the hemodynamic effects of the novel beta-adrenergic blocking agent KO.1366 (bunitrolol).
• To assess the impact of KO.1366 on heart rate, cardiac pressures, and output in patients with chest pain.

Main Methods:

• Intravenous administration of KO.1366 (0.05 mg/kg) to 10 male patients.
• Hemodynamic measurements at rest, during atrial pacing (100 beats/min), and hand grip exercise.
• Comparison of parameters before and after drug administration.

Main Results:

• Significant reduction in resting (12%) and exercise (4%) heart rates.
• Increase in resting left ventricular end-diastolic pressure (2.2 mm Hg) without changes during pacing or exercise.
• Slight increase in cardiac output and considerable increase in stroke volume at rest and during exercise.

Conclusions:

• KO.1366 (bunitrolol) exhibits a notable chronotropic effect on the heart.
• The drug does not appear to cause significant myocardial depression at the tested dosage.
• Bunitrolol shows potential as a therapeutic agent for conditions involving elevated heart rate.